Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
Alembic Pharmaceuticals targets low double-digit consolidated revenue growth in FY '27, driven by internal performance improvements amid stable external market conditions. - U.S. Alembic expects low double-digit consolidated top-line growth in FY '27 driven by international generics, API, and India businesses.
From Alembic Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Alembic Pharmaceuticals targets low double-digit consolidated revenue growth in FY '27, driven by internal performance improvements amid stable external market conditions.
- U.S. business expected to grow 10-15% in INR terms (approximately 7-8% in constant currency).
- Rest of World (ex-U.S.) markets projected to grow 15%+ driven by new product launches and expanding footprints.
- API business anticipated to grow around 10%, supported by volume increases.
- India business aims to improve growth momentum, targeting growth closer to the overall market.
- New product launches, especially Day 1 and First-to-File opportunities, along with contract manufacturing, will support volume growth.
- The U.S. branded business is in a launch phase, expected to scale and contribute meaningfully in the next few quarters.
- R&D investments continue to underpin growth through innovation and complex product development.
Profitability & Margins
See what Alembic Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Alembic Pharmaceuticals is broadly done with all major capex, including peptide-related investments, which were part of ongoing API facility upgrades rather than dedicated peptide capex.
- The branded business, including U.S. specialty branded operations like Pivya, does not require significant capex; investments are primarily in in-licensing products.
- For FY '27, capital expenditure is expected in the range of INR 300-350 crores, focused on capacity expansion, debottlenecking, and replacement capex.
- There will be continued, though measured, R&D investments (~INR 750-800 crores) to support complex products and expansion of the branded business.
- New product launches, increased utilization of F2 and F3 facilities, and contract manufacturing deals contribute to strategic growth without significant new capex.
- Strategic focus remains on quality portfolio additions, operating leverage, working capital management, and calibrated brand business expansion.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alembic Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Alembic Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.8K Cr, net profit ₹202 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alembic Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Alembic Pharmaceuticals Ltd Q4 FY26 results?
Alembic Pharmaceuticals targets low double-digit consolidated revenue growth in FY '27, driven by internal performance improvements amid stable external market conditions. - U.S. Alembic expects low double-digit consolidated top-line growth in FY '27 driven by international generics, API, and India businesses.
What is Alembic Pharmaceuticals Ltd share price analysis?
Alembic Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 21.6 with a market cap of ₹16,083 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alembic Pharmaceuticals Ltd planning capital expenditure?
Alembic Pharmaceuticals is broadly done with all major capex, including peptide-related investments, which were part of ongoing API facility upgrades rather than dedicated peptide capex. - The branded business, including U.S.
Keep Alembic Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.